Orfiril Retard (Sodium Valproate)

Sodium valproate, the active ingredient in Orfiril Retard, is an anticonvulsant presented as an extended‑release tablet for oral use. It treats generalized tonic‑clonic, absence and myoclonic seizures, and is also used for mood stabilization in bipolar disorder and migraine prevention in adults. GNH USA supplies Orfiril Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril Retard is an antiepileptic medication that acts on neuronal excitability in seizure disorders and related neurological conditions. - Generalized tonic‑clonic seizures: helps achieve seizure freedom or reduction in seizure frequency. - Absence seizures: decreases the number of typical absence episodes. - Myoclonic seizures: reduces the occurrence of rapid, shock‑like jerks. - Bipolar disorder (mood stabilization): assists in preventing manic and depressive episodes. - Migraine prophylaxis: lowers the frequency of migraine attacks.

Adverse reactions to sodium valproate may vary in frequency and severity.

Common Side Effects: - Nausea or upset stomach - Tremor or mild shakiness - Weight gain or increased appetite - Hair loss or thinning - Drowsiness or fatigue - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver injury or hepatic failure - Pancreatitis (inflammation of the pancreas) - Blood dyscrasias including agglutin­    -     

Orfiril